Wire · opportunities
FDA clears blood test to aid evaluation for Alzheimer's disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
The FDA cleared PrecivityAD2, a blood test developed by WashU Medicine and C2N Diagnostics, to aid Alzheimer's diagnosis by detecting amyloid plaque biomarkers with over 90% accuracy. This test offers a less invasive alternative to spinal taps and brain scans and supports earlier treatment initiation.
This Wire brief sits within Fusion42's coverage of Digital Health, and 7 sources have reported it between 20 Aug 2026 and 21 Aug 2026.
◆ ◆ The Wire takeaway
You now have FDA-backed access to a less invasive Alzheimer’s diagnostic tool that can speed patient diagnosis and treatment uptake. Healthtech founders should engage insurers and clinicians to scale adoption before competitors enter.
◆ Coverage
7 sources · first reported 20 Aug 2026 · latest 21 Aug 2026
◆ Related on Wire
◆ Topics